Protara Completes Enrollment in Phase 2b Trial for IV Choline Chloride

  • Protara Therapeutics completed enrollment of 24 patients in the Phase 2b open-label dose confirmation phase of the THRIVE-3 trial for IV Choline Chloride.
  • Interim results from this cohort are expected in 4Q 2026.
  • The trial targets patients with intestinal failure dependent on parenteral support and choline deficiency.
  • IV Choline Chloride has Orphan Drug and Fast Track designations from the FDA.
  • The Phase 3 trial will involve approximately 100 patients in a randomized, double-blind, placebo-controlled study.

Protara's progress in the THRIVE-3 trial positions IV Choline Chloride as a potential first-of-its-kind treatment for choline deficiency in parenteral support patients. The trial's completion of enrollment marks a critical step toward addressing a significant unmet need in liver function management for patients with intestinal failure. The strategic significance lies in the potential to tap into a niche but critical market segment, leveraging regulatory advantages to expedite market entry.

Regulatory Pathway
Whether the Fast Track and Orphan Drug designations will accelerate FDA approval for IV Choline Chloride.
Clinical Efficacy
The pace at which interim results from the Phase 2b cohort will demonstrate safety and efficacy in elevating plasma choline levels.
Market Potential
How the approval and commercialization of IV Choline Chloride will impact the approximately 30,000 long-term parenteral support patients in the U.S.